HOME >> MEDICINE >> NEWS
OHSU scientists test medication to treat involuntary weight loss

s to develop and test a medication that would have the same effect. This medication, and others in its class, have excellent oral absorption, which also enhances their appeal as drug candidates.

In this research, the scientists gave both normal mice and mice with a cachexia-like syndrome Neurocrine's orally-administered medication that blocks the MC4 receptor in the brain. In both cases, the animals' appetites increased and their metabolic rates decreased, ultimately resulting in the resumption of normal growth and accumulation of muscle mass. Researchers now hope to conduct clinical trials where both healthy human patients and those suffering from cachexia receive related oral medications to determine the drug's safety and effectiveness.

"We believe the results obtained in this collaborative study with OHSU will provide an important proof-of-principle for Neurocrine's small molecule MC4 receptor antagonist program in animal models relevant for cachexia," said Alan C Foster, Ph.D., Neurocrine Fellow and head of Neurocrine's neuroscience group. Neurocrine is a San Diego-based company that is developing medications related to weight regulation. "We hope to advance an optimized molecule into the first stages of human clinical testing later this year."

"While a lot of attention is paid to the country's obesity epidemic, researchers at OHSU also investigate the other side of weight regulation which is not as well-publicized -- extreme weight loss," said Roger Cone, Ph.D., director of the Center for the Study of Weight Regulation and Associated Disorders. "Cachexia and disorders like it can have extremely serious consequences on patients. This research not only provides hope for these patients, it is also provides another important piece of the puzzle in regards to the brain's control over weight regulation."

The Center for the Study of Weight Regulation and Associated Disorders is a new research institute at Oregon Health & Science
'"/>

Contact: Jim Newman
newmanj@ohsu.edu
503 494-8231
Oregon Health & Science University
29-Mar-2005


Page: 1 2 3

Related medicine news :

1. Earlier use of prostate cancer vaccines urged by Hopkins scientists
2. Tobacco industry pays scientists to challenge secondhand smokes link to infant death risk
3. Schepens scientists regenerate optic nerve for the first time
4. OHSU scientists develop MRI approach to improve breast cancer detection
5. UCLA neuroscientists pinpoint new function for mirror neurons
6. Jefferson scientists uncover potential trigger of diabetic kidney disease
7. Johns Hopkins scientists receive presidential medals
8. UCLA brain scientists crack mystery of how alcohol causes intoxication
9. Wisconsin scientists grow critical nerve cells
10. Jefferson scientists help explain statins effects in Alzheimers disease
11. Jefferson scientists find zinc may help prevent esophageal, oral cancers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/17/2017)... ... February 17, 2017 , ... ... services, announced today that Karen Pilley has been promoted to Chief Executive Officer. ... today’s shifting healthcare paradigm – a shift that demands the transition from pay-for-service ...
(Date:2/17/2017)... ... February 17, 2017 , ... Like most hospitals across the nation, Onslow Memorial ... by the Hospital Readmission Reduction Program (HRRP), the return of a patient to the ... across the nation. While many providers are struggling to leverage limited resources and technology, ...
(Date:2/16/2017)... ... February 17, 2017 , ... ... took over 10 years of research, development and clinical trials, the founder of ... is a patented compound of FDA approved ingredients that when infused into alcohol, ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... and superiority in patient care, NWH has achieved Magnet® recognition for ... Tuesday, January 31, 2017. The American Nurses Credentialing Center’s Magnet Recognition Program® distinguishes ...
(Date:2/16/2017)... ... February 16, 2017 , ... A February 6 ... as fat freezing or CoolSculpting, noting that some 425,000 procedures were performed with the ... that the clinic is, in fact, seeing a great deal of interest from area ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... YORK , Feb. 17, 2017  Noble Capital ... on ESSA Pharma Inc. (Nasdaq: EPIX ). ... Research, Kumar Raja , PhD. ESSA ... for castration resistant prostate cancer (CRPC). Its lead compound ... blocks the amino-terminal domain of the androgen receptor, thereby ...
(Date:2/16/2017)... , Feb. 16, 2017 The global ... USD 7.88 billion by 2021 from USD 5.49 billion ... On the basis of type, the preparative and ... preparative chromatography. In 2016, the process chromatography segment is ... global preparative and process chromatography. Growth in this segment ...
(Date:2/16/2017)... , Feb. 16, 2017  AcelRx Pharmaceuticals, Inc. ... company focused on the development and commercialization of ... pain, announced that Vincent J. Angotti ... member of the company,s board of directors, effective ... two decades of experience leading executive and commercial ...
Breaking Medicine Technology:
Cached News: